By using this site, you agree to our Privacy Policy and our Terms of Use. Close
SvennoJ on 18 May 2020
Edit Thread

Some good news to offset the racism, sexism, warmongering and letting the old people die for the sake of the economy.

https://www.ctvnews.ca/health/coronavirus/early-results-from-moderna-vaccine-trial-show-participants-developed-antibodies-against-coronavirus-1.4943881

Study subjects who received Moderna's COVID-19 vaccine had positive early results, according to the biotech company, which partnered with the National Institutes of Health to develop the vaccine. If future studies go well, the company's vaccine could be available to the public as early as January, Dr. Tal Zaks, Moderna's chief medical officer, told CNN.

Moderna has vaccinated dozens of study participants and measured antibodies in eight of them. All eight developed neutralizing antibodies to the virus at levels reaching or exceeding the levels seen in people who've naturally recovered from COVID-19, according to the company. Neutralizing antibodies bind to the virus, disabling it from attacking human cells.

"We've demonstrated that these antibodies, this immune response, can actually block the virus," Zaks said. "I think this is a very important first step in our journey towards having a vaccine."


It's a phase 1 small trial, notyet  peer reviewed, lots of work left to be done. However nobody died while (some) developed anti bodies. Good result.

While the vaccine had promising results in the lab, it's not known if it will protect people in the real world. The U.S. Food and Drug Administration has cleared the company to begin Phase 2 trials, which typically involve several hundred of people, and Moderna plans to start large-scale clinical trials, known as Phase 3 trials, in July, which typically involve tens of thousands of people.


Atm 8 developers are doing clinical trials on vaccine candidate

In the Moderna study, three participants developed fever and other flu-like symptoms when they received the vaccine at a dose of 250 micrograms. Moderna anticipates the Phase 3 study on dosage will be between 25 and 100 micrograms. So far, the Moderna study subjects who were vaccinated even at 25 and 100 micrograms achieved antibody levels similar to or even higher than people who naturally became infected with coronavirus.

But it's not clear whether natural infection confers immunity to re-infection, and so similarly it's not clear whether vaccination confers immunity. "That's a good question, and the truth is, we don't know that yet," Zaks said. "We are going to have to conduct formal efficacy trials where you vaccinate many, many people, and then you monitor them in the ensuing months to make sure they don't get sick."